ALNYLAM PHARMACEUTICALS INC
831 institutions still hold ALNYLAM PHARMACEUTICALS INC as of Q2 2026. Tracked across SEC 13F-HR filings, with insider and 13D/G activity surfaced alongside.
Alnylam Pharmaceuticals' stock (ALNY, CUSIP 02043Q107) entered Q1 2026 with 754 institutional holders controlling $39.3B of positions across the 13F universe, making it one of the densest institutional-ownership names in healthcare. The quarter's signal is not accumulation — it is active rotation at the manager tier: FMR LLC cut by $1.5B (–9.4% of its position), Capital World Investors slashed by $2.9B (–17.8%), Invesco shed $434M, Baillie Gifford trimmed $209M, and Dodge & Cox decreased $143M. On the other side, Capital Research Global Investors added $438M (+64.8% increase), Two Sigma built a new $659M position (+$414M), Clearbridge entered with a $449M new stake (+$211M), JPMorgan added $122M, and Bank of America added $75M. Three Vanguard entities (Portfolio Management, Capital Management, Fiduciary Trust) are all shown as new positions totaling ~$2.9B. This is a textbook institutional rebalancing story — the smart-money consensus on ALNY's RNAi platform is not withdrawing, but the active-manager composition of the holder base is shifting.
Top holders
Sorted by position value. Source: SEC EDGAR 13F-HR filings.